Positron emission tomography for the diagnosis of breast cancer

被引：41

作者：

Rosé, C

Dose, J

Avril, N

机构：

[1] Univ Pittsburgh, Med Ctr, Div Nucl Med, Pittsburgh, PA 15213 USA

[2] Tech Univ Munich, Dept Nucl Med, D-8000 Munich, Germany

[3] Univ Hosp Hamburg Eppendorf, Dept Gynecol, Hamburg, Germany

来源：

NUCLEAR MEDICINE COMMUNICATIONS | 2002年 / 23卷 / 07期

关键词：

breast cancer; positron emission tomography; 18F]fluorodeoxyglucose; diagnosis; staging;

D O I：

10.1097/00006231-200207000-00004

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

This article reviews the literature on breast imaging with [F-18]fluorodeoxyglucose positron emission tomography (FDG PET). In clinical applications, there is currently no defined role for detecting primary breast cancer. The limited sensitivity of FDG PET does not allow the exclusion of malignancy, in particular small breast carcinomas, micrometastases and small, tumour infiltrated lymph nodes. However, in advanced stages, PET accurately determines the extent of disease, including the loco-regional lymph node status. Furthermore, whole-body PET imaging promises a high diagnostic accuracy for detecting recurrent or metastatic breast carcinoma. Future clinical applications may include monitoring therapeutic effects. ((C) 2002 Lippincott Williams Wilkins).

引用

页码：613 / 618

页数：6

共 40 条

[1] Axillary lymph node metastases: Screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET [J].